Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals. by Casanova, Ramon et al.
Blood metabolite markers of preclinical Alzheimer’s disease in 
two longitudinally followed cohorts of older individuals
Ramon Casanova, PhD1, Sudhir Varma, PhD2, Brittany Simpson, BA3,4, Kim Min, MSci5, 
Yang An, MS3, Santiago Saldana, MS1, Carlos Riveros, PhD6, Pablo Moscato, PhD6, 
Michael Griswold, PhD7, Denise Sonntag, PhD8, Judith Wahrheit, PhD8, Kristaps Klavins, 
PhD8, Palmi V Jonsson9, Gudny Eiriksdottir9, Thor Aspelund9, Lenore J Launer10, 
Vilmundar Gudnason9, Cristina Legido Quigley, PhD5, and Madhav Thambisetty, MD, PhD3
1Wake Forest School of Medicine, Winston, Salem, NC, USA 2HiThru Analytics LLC, Laurel, MD, 
USA 3Clinical and Translational Neuroscience Unit, National Institute on Aging, National Institutes 
of Health, Baltimore, MD, USA 4School of Medicine, University of Mississippi Medical Center, 
Jackson, MS, US 5King’s College, London, United Kingdom 6University of Newcastle, Callaghan, 
Australia 7Center of Biostatistics and Bioinformatics, University of Mississippi Medical Center, 
Jackson, MS, US 8BIOCRATES Life Sciences AG, Innsbruck, Austria 9Icelandic Heart 
Association, Kopavogur, Iceland 10Laboratory of Epidemiology, Demography and Biometry, 
National Institute on Aging, Bethesda, Maryland
Abstract
Recently, quantitative metabolomics identified a panel of 10-plasma lipids that were highly 
predictive of conversion to Alzheimer’s disease (AD) in cognitively normal older individuals 
(N=28, area-under-the-curve; AUC=0.92, sensitivity/specificity of 90%/90%). We failed to 
replicate these findings in a substantially larger study from two independent cohorts - the 
Baltimore Longitudinal Study of Aging (BLSA, N=93, AUC=0.642, sensitivity/specificity of 
51.6%/65.7%) and the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-RS, 
N=100, AUC=0.395, sensitivity/specificity of 47.0%/36.0%). In analyses applying machine 
learning methods to all 187 metabolite concentrations assayed, we find a modest signal in the 
BLSA with distinct metabolites associated with the preclinical and symptomatic stages of AD, 
whereas the same methods gave poor classification accuracies in the AGES-RS samples. We 
believe that ours is the largest blood biomarker study of preclinical AD to date. These findings 
underscore the importance of large-scale independent validation of index findings from biomarker 
studies with relatively small sample sizes.
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 1. INTRODUCTION
Non-invasive and accurate peripheral biomarkers of preclinical Alzheimer’s disease (AD) 
are a critical unmet need. The recent incorporation of cerebrospinal fluid (CSF) and imaging 
biomarkers into the diagnostic guidelines for AD, mild cognitive impairment (MCI) and 
preclinical AD represent a paradigm shift in the field [1–3]. The application of 
metabolomics technology for the discovery of AD biomarkers is receiving increasing 
attention [4]. As small metabolites represent the end result of cellular regulatory complexity, 
they are thought to be reliable proximal reporters of disease processes [5]. Several studies 
have reported on alterations in metabolite concentrations in blood between AD and healthy 
controls [6–12]. Most of these previous studies have relied upon relatively small sample 
sizes and different methodological approaches making comparative assessment of results 
difficult. Moreover, very few studies have focused attention on the discovery of predictive 
biomarkers of AD i.e. those indicative of greater risk of subsequent conversion to AD in 
older individuals who are cognitively normal. Such biomarkers would represent a substantial 
breakthrough as they would allow for the effective screening of large numbers of at-risk 
elderly and facilitate the testing of disease-modifying treatments in patients in very early 
stages of the AD disease process. If such biomarkers could accurately identify cognitively 
normal elderly at risk of subsequent AD, they would be of immediate clinical utility and 
merit use in routine clinical practice.
A recent study reported the discovery of a 10-metabolite panel in plasma that could 
discriminate cognitively normal older individuals who developed incident AD within 3 years 
(n=10; validation sample; age; 79.3±5.49 years) from healthy controls who remained 
cognitively normal (n=20; validation sample; age; 81.35±3.25 years) [13]. This panel was 
described as having impressive accuracy (0.92 area-under-the-receiver-operating-
characteristic-curve; sensitivity/specificity; 90%/90%), suggesting considerable clinical 
utility of these analytes as antecedent biomarkers of memory impairment in cognitively 
normal individuals who will eventually develop AD.
Here, we test these index findings in a substantially larger sample from two well-
characterized and longitudinally followed cohorts of older individuals from North America 
and Europe-the Baltimore Longitudinal Study of Aging (BLSA) [14] and the Age, Gene/
Environment Susceptibility Study-Reykjavik (AGES-RS) [15] using the same targeted 
metabolomics platform utilized in the index study [13] (AbsoluteIDQ p180 assay, 
BIOCRATES, Life Science AG, Innsbruck, Austria). We examined serum metabolomic 
profiles at two time points for two groups – ‘non-converters’ who remained cognitively 
normal between 2 time points, approximately 5 years apart, and ‘converters’ who were 
cognitively normal at baseline and converted to AD within the same interval as the non-
converters. In addition to testing whether we could replicate the previously reported findings 
by Mapstone and colleagues using their 10-metabolite panel [13], we also used a data-driven 
approach using machine-learning methods to analyze the entire targeted metabolomic data 
we acquired to examine whether other metabolite signatures could be identified as predictors 
of incident AD.
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 2. METHODS
 2.1BLSA and AGES-RS cohorts
Several previous publications have described details of the BLSA [14, 16, 17] and AGES-RS 
cohorts [15, 18]. A summary of participant characteristics and study procedures, including 
diagnostic approaches to AD/dementia in the two studies are included in supplementary 
material.
 2.2 Serum samples
Serum samples were collected after overnight fasting in both BLSA and AGES-RS 
participants fasting (between 6 and 7 AM in BLSA and between 8AM-11 AM in AGES-
RS). Details of pre-analytical procedures including sample storage are provided in 
supplementary material. BLSA participants who were cognitively normal at baseline and 
developed AD during follow up (i.e. ‘converters’: BLSA; n=93; baseline age 77.9±6.5 years) 
were age- and sex-matched to participants who remained cognitively normal throughout 
follow up (i.e. ‘non-converters’: BLSA; n=99, baseline age 76.6±6.7 years) in a case-control 
design (Table-1A). Two serial serum samples were analyzed from each participant in both 
the ‘converter’ and ‘non-converter’ groups (total number of serum samples assayed=384). 
Serial serum samples from the BLSA were obtained as follows:
i. Baseline: 5 years (4.8±1.2) prior to onset of cognitive impairment in 
individuals meeting consensus clinical diagnosis of incident AD (i.e. 
converters) and age-matched samples from healthy controls (i.e. non-
converters).
ii. Samples concurrent (0.69±0.83 years) to onset of cognitive impairment in 
individuals meeting consensus clinical diagnosis of incident AD (i.e. 
converters) and age-matched samples from healthy controls (i.e. non-
converters).
Serum samples from AGES-RS participants were obtained over the course of two separate 
waves of the study. Wave-1 was completed between 2002 and 2006 and wave-2, between 
2007 and 2011. 100 participants who were cognitively normal during wave-1 and 
subsequently diagnosed with AD during wave-2 (i.e. ‘converters’, baseline age 78.18±4.4) 
were age-and sex-matched 1:1 to 100 participants who remained cognitively normal over the 
course of both waves-1 and 2 (i.e. ‘non-converters’, baseline age 78.23±4.4). Baseline and 
follow-up samples were obtained at wave-1 and wave-2 respectively in both converter and 
non-converter groups. The average interval between baseline and follow-up samples was 
5.22±0.25 years (total number of serum samples assayed=400). We estimated the 
approximate time-to-conversion to AD in the converter group as the midpoint of the time 
interval between their baseline and follow-up samples (2.62±0.14 years) (Table-1B).
 2.3 Sample size, data exclusion and randomization
Using the previously published estimate of within-class standard deviation of 1.5 by 
Mapstone et al [13] for metabolite concentrations assayed on the AbsoluteIDQ p180 
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platform, we calculated that a sample size of 100 controls and 100 AD cases would achieve 
>85% power to detect a log-fold change of 1.5 between control and converter groups.
In the BLSA samples, data from one subject diagnosed with mild cognitive impairment 
(MCI) was excluded. Data from an additional seven subjects who only had serum samples at 
one time point were also excluded. In the AGES-RS samples data from all subjects were 
included.
Converter and control samples were randomly divided into 6 groups and each group 
processed in separate batches during acquisition of serum metabolite concentrations. Serum 
metabolite concentrations were assayed in a blinded manner to diagnoses. For analysis of 
serum metabolite data, we used rigorous cross validation (including metabolite selection) to 
estimate classifier accuracy in an unbiased manner.
 2.4 Data acquisition using BIOCRATES AbsoluteIDQ p180 metabolomics platform
BIOCRATES commercially available kit plates were used for the quantification of amino 
acids, acylcarnitines, sphingomyelins, phosphatidylcholines, hexoses, and biogenic amines. 
This validated assay uses two different mass spectrometric methods with isotope labelled 
and other internal standards for quantification. The acylcarnitines, lipids, and hexose are 
analyzed by flow injection analysis mass spectrometry (FIA-MS/MS). The amino acids and 
biogenic amines are subjected to phenylisothiocyanate (PITC)-derivatization and analyzed 
by HPLC-MS/MS using an AB SCIEX 4000 QTrap® mass spectrometer (AB SCIEX, 
Darmstadt, Germany) with electrospray ionization. A more detailed description of the assay 
can be found elsewhere [19]. The analytical platform was identical to that reported 
previously by Mapstone and colleagues [13].
 2.5 Data reproducibility and variation within groups
The AbsoluteIDQ p180 platform yielded data that was highly reproducible with a median 
coefficient of variance of 5.3% (6.4% in AGES-RS) with 86% (90% in AGES-RS) of 
metabolites measured with CV<15% (calculated using quality control spike-in plasma 
samples). Equality of variance between groups was tested using the Levene test for 
homogeneity of variance. In the BLSA samples, 163 metabolites passed the test with a false 
detection ratio (FDR) > 0.05. In the AGES-RS data, all 187 metabolites passed the test with 
FDR>0.05. Normality of data within each group was not tested since the machine learning 
algorithms we used do not assume normality.
 2.6 Evaluation of classifiers performance
Absolute serum concentrations of 187 targeted metabolites (including the 10 reported 
previously1) were analyzed for discrimination between converters and non-converters at both 
time points (i.e. ‘baseline’ and ‘follow-up’). Average values of classification accuracy (area-
under-the-receiver-operating-characteristic-curve, AUC), and sensitivity/specificity (using 
disease probability thresholds of 0.5) were derived using several machine learning methods 
(elastic net regularized logistic regression (EN-RLR), random forest classifier (RF), support 
vector machines (SVM) and L1 regularized logistic regression (L1-RLR) (supplementary 
material and supplementary table-1) to assess how well these serum metabolite 
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concentrations discriminated between converter and non-converter samples. To avoid 
upward bias in the estimation of these metrics, we divided our data into training and testing 
sets. The 192 samples in BLSA and 200 samples in AGES-RS were thus split 80%/20% 
(BLSA; 152/40 and AGES-RS; 160/40 samples) for training and testing respectively. To 
account for variability due to random partitioning of training/testing data, the process was 
repeated 100 times and the performance metrics averaged over the 100 splits. The proportion 
of converters: non-converters was maintained approximately at 1:1 after partitioning.
 3.0 RESULTS
The demographic characteristics of participants from the BLSA and AGES-RS-RS studies 
included in this report are described in Table-1A and B.
First, we used an identical logistic regression model applied by Mapstone et al. [13] to test 
the accuracy of their 10-metabolite panel as a predictor of preclinical AD in our cohorts. In 
the BLSA samples, this panel gave an area-under the-curve (AUC) of 0.64 and sensitivity/
specificity of 51.6%/65.7% for discriminating baseline converter samples (i.e. pre-
conversion) from non-converters. In the AGES-RS samples, the 10-metabolite panel gave an 
AUC of 0.394 and sensitivity/specificity of 47%/36% for discriminating baseline converter 
samples (i.e. pre-conversion) from non-converters. In comparison, Mapstone and colleagues 
reported an AUC of 0.92 and sensitivity/specificity of 90%/90% for discrimination between 
baseline converter and non-converter groups.
Next, we tested the 10-metabolite panel as a biomarker of current disease using the same 
logistic regression model to discriminate samples concurrent to symptom onset in converters 
(i.e. post-conversion) versus non-converters. In the BLSA samples, this analysis yielded an 
AUC of 0.58 and sensitivity/specificity of 53.8%/62.6%. In the AGES-RS samples, the 10-
metabolite panel gave an AUC of 0.481 and sensitivity/specificity of 52%/48% for 
discriminating AD samples (i.e. post-conversion) from non-converters. In comparison, the 
index study reported an AUC of 0.77 for discrimination between post-conversion and non-
converter samples (sensitivity/specificity were not reported for this analysis) [13].
Next, we analyzed the entire metabolite dataset of 187 metabolites without a priori 
hypotheses about the nature and/or identity of candidate AD biomarkers. In the BLSA 
samples, a Random Forest (RF) classifier discriminated pre-conversion samples from non-
converters with a classification accuracy of 64.2% and sensitivity/specificity of 55.5%/
73.0%. L1-Regularized Logistic Regression (L1-RLR) gave the best discrimination between 
samples concurrent to symptom onset (i.e. post-conversion) versus non-converters with 
classification accuracy of 67.2% and sensitivity/specificity of 67.7%/66.7%. Two additional 
algorithms i.e. Support Vector Machine (SVM) and Elastic Net-Regularized Logistic 
Regression (EN-RLR) yielded similar performance characteristics (supplementary table-1). 
Different metabolites, in particular phospholipids with fatty acid chains (summed to C30 to 
C44 carbon-carbon bonds) appeared to be important in discrimination between pre- and 
post-conversion samples relative to non-converters (supplementary table-2), suggesting that 
alterations in distinct metabolic pathways may underlie the pre-symptomatic and 
symptomatic phases of AD.
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In the AGES-RS samples, our machine learning analyses demonstrated poor discrimination 
between both pre-conversion and non-converters as well as post-conversion samples relative 
to non-converters. All the classifiers tested showed performance metrics similar to random 
classification of samples between groups. The L1-RLR classifier yielded classification 
accuracy of 46.5%, sensitivity/specificity of 45%/48% for pre-conversion samples and 
slightly better but substantially similar results for post-conversion samples. The other three 
classifiers gave similar results (not presented).
 4.0 DISCUSSION
An accurate and non-invasive blood biomarker associated with preclinical AD is likely to 
revolutionize the care of patients with this devastating disease and accelerate the 
development of novel disease-modifying treatments by targeting them in individuals at 
greatest risk. The identification of such blood biomarkers is therefore likely to be of 
immediate benefit to patients and their caregivers in clinical as well as research settings. A 
recent report that a panel of ten plasma metabolites in blood could accurately predict 
conversion to AD in cognitively normal older individuals, raised hope that such biomarkers 
are within reach and received wide attention both within and outside the scientific 
community [13, 20]. However, other high profile biomarker findings in the AD field have 
not been replicated [21, 22], highlighting the need for large-scale confirmatory studies 
performed in well-characterized cohorts [23].
In this report, we first attempted to confirm the index findings by Mapstone et al. using the 
same metabolomics platform and analytical methodology used in their report. We undertook 
these analyses in two independent cohorts from longitudinal studies of normal aging i.e the 
BLSA and AGES-RS studies. We assayed metabolite concentrations from nearly 800 serial 
serum samples and found that we were unable to replicate the high performance metrics of 
the 10-metabolite panel in the sample of 28 converters reported in the index study. To the 
best of our knowledge, our current report is the largest blood biomarker study of preclinical 
AD to date.
It is important to first consider the major methodological differences between the current 
report and that of Mapstone et al. These are summarized in table-2. The most obvious 
consideration is the choice of matrix used to measure metabolite concentrations. Whereas 
the original study assayed plasma, we used serum samples in our study. However, recent 
studies have provided strong evidence for a high concordance between concentrations of 
metabolites assayed in plasma versus serum on the BIOCRATES AbsoluteIDQ™ platform. 
In a large study sample from participants in the Cooperative Health Research in the Region 
of Augsburg (KORA) (n=377; 180 female, 197 male, age range from 51 to 84 years), Yu and 
colleagues reported on the concordance between plasma versus serum concentrations of 122 
metabolites assayed on the BIOCRATES AbsoluteIDQ™ platform [24]. Using their 
published data (available at: http://journals.plos.org/plosone/article?id=10.1371/
journal.pone.0021230#s5), we examined the correlation between plasma and serum for each 
of the 10 metabolites reported by Mapstone et al. These findings are summarized in table-3 
and show that most of these metabolites are highly correlated between the two matrices, 
with seven of the 10 analytes showing a correlation coefficient >0.85. Taken together, these 
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previous reports clearly establish that the majority of metabolite concentrations measured 
using the BIOCRATES AbsoluteIDQ™ method, and especially the ten metabolites reported 
by Mapstone et al. are highly correlated between plasma and serum. Therefore differences in 
the matrix used between our report and the index publication are unlikely to account for our 
inability to replicate the previously reported results.
The second major factor that could potentially account for differences between our results 
and those previously reported is the time-to-conversion to AD. Cognitively normal 
participants in the original report developed AD or mild cognitive impairment (MCI) over an 
average follow-up interval of 2.1 years, whereas those in the BLSA had an average time to 
symptom onset of 4.8 years. We therefore analyzed samples from an independent cohort of 
older individuals from the AGES-RS study with an estimated average time-to-conversion to 
AD (2.62±0.14 years) that was more similar to that reported in Mapstone et al. to confirm 
that our failure to replicate the index findings were not driven by a slightly longer time to 
symptom onset in the BLSA cohort. It is also worth noting here that our inability to replicate 
the previous findings extend to both the prediction of subsequent AD in cognitively normal 
individuals (i.e. pre-conversion versus non-converters) as well as the discrimination between 
AD (i.e. post-conversion) and non-converter samples. If the inconsistencies in results were 
due entirely to differences in time-to-symptom onset, we would expect replication of the 
previous findings at least as markers of concurrent disease.
We also considered whether duration of sample storage may account for the inconsistency in 
results between our study and the index study. In their report, Mapstone and colleagues did 
not provide details on either the duration of sample storage or when participant recruitment 
to their study began. We are therefore unable to determine whether differences in duration of 
sample storage may contribute to the inconsistent results. In both the BLSA and AGES-RS 
studies, serum samples were collected after overnight fasting in standard serum separator 
tubes, centrifuged and stored in cryovials at −80°C until further use. The mean duration of 
serum sample storage ranged from 15.67±8.12 years in the BLSA and 8.04±2.77 years in the 
AGES-RS study. Serum aliquots used in our current report were not subject to additional 
freeze-thaw prior to the metabolomics assays reported herein. Breier et al. have examined 
the role of several pre-analytical variables such as sample storage duration, temperature and 
freeze-thaw cycles in targeted metabolomics analyses in blood using the BIOCRATES 
AbsoluteIDQ™ assay [25]. They conclude that the majority of metabolites measured are 
stable for up to 24 hours on cool packs and at room temperature even in non-centrifuged 
tubes. Additionally, serum metabolite concentrations were mostly unaffected by tube type 
and one or two freeze-thaw cycles. However, as some amino acids and biogenic amines may 
be unstable on cool packs, the authors recommend that blood samples be processed and 
frozen immediately after collection, as was done in both the BLSA and AGES-RS studies. 
We believe therefore, that serum metabolite concentrations measured in the BLSA and 
AGES-RS samples reported herein, followed optimal sampling conditions and storage times. 
Hence this pre-analytical variable i.e. sample storage duration is also unlikely to account for 
our failure to replicate the index findings of Mapstone et al.
Having assessed obvious methodological differences between our current study and that of 
Mapstone et al. which may account for the inconsistent results, we next considered the 
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analytical procedures adopted to examine the metabolomics data derived in the respective 
studies. Our first analysis was based on an a priori selection of the 10 metabolites reported in 
the original study. The index report provides few details about how these 10-metabolites 
were eventually selected from the approximately 180 that are assayed on the BIOCRATES 
AbsoluteIDQ™ platform [13]. Thus it is unclear how these data were processed, the exact 
procedures followed in constructing the final classifier and what, if any measures were 
adopted to avoid overfitting bias in estimating the performance metrics of the 10 
metabolites. After our primary analysis with the a priori selected 10 metabolites that failed 
to replicate their original results, we examined the entire metabolomics data acquired in both 
BLSA and AGES-RS samples using machine learning approaches. By using rigorous 
partitioning of samples into training/test sets in two independent samples from the BLSA 
and AGES-RS studies, we guarded against over-fitting of data which is a common cause of 
inflated classification accuracies while using high-dimensional datasets such as 
metabolomics and proteomics on relatively small sample sizes [26]. In both the BLSA and 
AGES-RS samples, the analyses did not reveal a high level of discrimination between 
groups based on serum metabolite concentrations. In the BLSA, consensus metabolites were 
modestly associated with pre-symptomatic and symptomatic stages of AD and appeared to 
represent distinct metabolic pathways.
In conclusion, we were unable to replicate the high prediction performance for detecting 
preclinical AD reported previously for a metabolite panel assayed on the same platform 
using a substantially larger sample size drawn from two independent well-characterized 
longitudinal cohorts. Our study further underscores the importance of well-designed 
validation of exploratory biomarker studies. While the emerging technology of 
metabolomics holds great promise in epidemiological studies to accurately measure 
environmental exposure and quantify risk factors, our current report highlights the 
importance of performing large-scale replication of findings emerging from small index 
studies [27].
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in context
Systematic review
We first reviewed (using PubMed) all publications reporting the use of metabolomics in 
plasma/serum of AD patients and healthy controls. Few studies have used metabolomics 
to discover blood biomarkers of preclinical AD. A recent report identified a 10-
metabolite panel in blood that could predict risk of conversion to AD in cognitively 
normal individuals with greater than 90% accuracy. Using the same targeted 
metabolomics method, we tried to confirm these results in a substantially larger study 
using more than 700 serial serum samples from two well-characterized, longitudinally 
followed cohorts of older individuals.
Interpretation
We were unable to replicate the recent findings implicating a panel of 10 metabolites as 
highly accurate blood biomarkers of preclinical AD. Our results underscore the need for 
large-scale validation of small exploratory biomarker studies.
Future directions
Future studies that expand the number and classes of analytes beyond those reported here 
will be required to discover novel blood metabolite biomarkers of AD. Such studies will 
require independent validation in well-characterized samples to establish their clinical 
utility.
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Table 1A
Demographic characteristics of BLSA participants whose serum samples were analyzed in the current report. 
Data presented as mean (standard deviation).
Whole Sample Control AD DIFFERENCE (P-VALUE)
N 192 99 93
Sex (F/M) 94/98 44/55 50/43 0.20
Age at first serum sample analyzed (years) 77.2 (6.6) 76.6 (6.7) 77.9 (6.5) 0.13
Age at second serum sample analyzed (years) 81.5 (6.2) 81.0 (6.2) 82.0 (6.3) 0.18
Interval between first and second samples analyzed (years) 4.3 (1.2) 4.4 (1.2) 4.1 (1.1) 0.11
Education (years) 16.4 (2.8) 16.2 (3.0) 16.5 (2.5) 0.75
Interval between pre-conversion sample and onset of cognitive 
impairment (years)
4.8 (1.2)
Interval between post-conversion sample and onset of cognitive 
impairment (years)
0.69 (0.83)
The differences between Control group and AD groups were tested using Mann–Whitney U test for continuous variables and Chi-Square test for 
categorical variables.
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Table 1B
Demographic characteristics of AGES-RS participants whose serum samples were analyzed in the current 
report. Data presented as mean (standard deviation).
Whole Sample Control AD DIFFERENCE (P-VALUE)
N 200 100 100
Sex (F/M) 109/91 55/45 54/46
Age at first serum sample analyzed (years) 78.20 (4.38) 78.23 (4.39) 78.18 (4.40) −0.05 (0.934)
Age at second serum sample analyzed (years) 83.43 (4.42) 83.43 (4.41) 83.43 (4.45) 0.00 (0.978)
Interval between first and second samples analyzed (years) 5.22 (0.25) 5.20 (0.20) 5.24 (0.29) 0.04 (0.379)
Education* 2.03 (0.91) 2.17 (0.95) 1.90 (0.85) −0.27 (0.048)
Interval between pre-conversion sample and onset of 
cognitive impairment (years)
2.62 (0.14)
Interval between post-conversion sample and onset of 
cognitive impairment (years)
2.62 (0.14)
The differences between Control group and AD groups were tested using Mann–Whitney U test for continuous variables and Chi-Square test for 
categorical variables.
*
Education was graded semi-quantitatively according to the highest level of completed education as follows: 1-primary school or less; 2-secondary 
school; 3-college; 4-University degree.
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Table 2
Comparison of participant characteristics, study design, experimental methodology and results between the 
index study by Mapstone et al [13] and the current report.
Blood samples analyzed Mapstone et al. Current report
BLSA AGES-RS
Healthy controls 73 99 100
Converters with both pre- and post-
conversion samples
28§ 93 100
Age at sampling
Healthy controls; baseline 81.49 (3.48) 76.6 (6.7) 78.23 (4.39)
Healthy controls; follow-up Not reported 81.0 (6.2) 83.43 (4.41)
Pre-conversion 80.21 (4.02) 77.9 (6.5) 78.18 (4.40)
Post-conversion 82.23 (3.95) 82.0 (6.3) 83.43 (4.45)
Follow-up interval
Pre-conversion sample to symptom 
onset (years)
2.1 4.8 (1.2) 2.62 (0.14)
Sex (F/M) 62/39 94/98 109/91
Healthy controls 46/27 44/55 55/45
Converters 16/12 50/43 54/46
Education (years)
Healthy controls 15.52 (2.36) 16.2 (3.0) 2.17 (0.95)*
Converters 15.04 (2.74) 16.5 (2.5) 1.9 (0.85)*
Sample assayed Plasma Serum Serum
Metabolomics assay used AbsoluteIDQ p180 BIOCRATES AbsoluteIDQ p180 BIOCRATES
Performance metrics of 10-metabolite 
panel described in Mapstone et al.
Pre-conversion versus controls AUC/
Sensitivity/Specificity
0.92/90%/90% BLSA
0.642/51.6%/65.7%
AGES-RS
0.395/47.0%/36.0%
Post-conversion versus controls AUC/
Sensitivity/Specificity
0.77 sensitivity/specificity not 
reported
0.575/53.8%/62.6% 0.482/52.0%/48.0%
Unbiased assessment of all targeted 
metabolites assayed
Methodology Not reported All 187 metabolite levels assessed as potential AD 
biomarkers using multiple machine learning classifiers 
without a priori assumptions**
Pre-conversion versus controls 
Accuracy/Sensitivity/Specificity
Not reported BLSA
0.642/55.5%/73.0%
AGES-RS
0.415/45.0%/48.0%
Post-conversion versus controls 
Accuracy/Sensitivity/Specificity
Not reported 0.672/67.7%%/66.7% 0.515/53.0%/50.0%
§
Details available at http://www.nature.com/nm/journal/v20/n4/extref/nm.3466-S1.pdf
**
Education was graded semi-quantitatively according to the highest level of completed education as follows: 1-primary school or less; 2-
secondary school; 3-college; 4-University degree.
**Only results from the L1-RLR classifier are reported for AGES-RS. Other classifiers tested yielded similar results.
Alzheimers Dement. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Casanova et al. Page 15
Table 3
Correlation coefficients (‘R between plasma and serum’) for concentrations of the 10-metabolites reported by 
Mapstone et al [13]. Data extracted from Yu, et al [24] (n=377; 180 female, 197 male, age range from 51 to 84 
years), and available online at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021230#s5
Metabolite names Mean ±SD (μM) in plasma Mean ±SD (μM) in serum Relative mean difference 
(%)
R between plasma and 
serum
PC aa C36:6 1.15 ± 0.49 1.27 ± 0.56 9.30 0.93
PC aa C38:6 82.47 ± 26.46 92.59 ± 28.9 11.43 0.90
PC aa C40:6 27.39 ± 9.51 30.27 ± 10.13 10.00 0.90
lysoPC a C18:2 26.13 ± 8.45 30.01 ± 9.82 13.68 0.89
PC aa C38:0 3.09 ± 0.84 3.52 ± 0.98 12.44 0.88
C3 0.04 ± 0.01 0.04 ± 0.02 7.00 0.86
PC ae C40:6 4.89 ± 1.28 5.51 ± 1.52 11.26 0.86
PC aa C40:1 0.41 ± 0.09 0.45 ± 0.1 7.70 0.79
PC aa C40:2 0.33 ± 0.09 0.37 ± 0.1 −26.2 0.33
C16:1-OH 0.01 ± 0.01 0.01 ± 0.01 0 0.01
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